Evidence map›Paper›PMID 38229055›Full record

ArticleBMC oral health2024

Changes in mandibular radiomorphometric indices in osteoporosis patients treated with denosumab: a retrospective case-control study.

Katia Rupel, Chiara Dal Broi, Giulia Ottaviani, Laura Bellassai, Theodora Magdalena Bogdan Preda, Roberto Di Lenarda, Matteo Biasotto

Open access · goldAbstract read
In one paragraph

Article in BMC oral health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Katia Rupel *Department of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume, n 447 - 34129, Trieste, Italy. krupel@units.it.ORCID 0000-0002-6150-9439
Chiara Dal Broi *Department of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume, n 447 - 34129, Trieste, Italy.
Giulia OttavianiDepartment of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume, n 447 - 34129, Trieste, Italy.
Laura BellassaiDepartment of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume, n 447 - 34129, Trieste, Italy.
Theodora Magdalena Bogdan PredaDepartment of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume, n 447 - 34129, Trieste, Italy.
Roberto Di LenardaDepartment of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume, n 447 - 34129, Trieste, Italy.
Matteo BiasottoDepartment of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume, n 447 - 34129, Trieste, Italy.
University of Trieste · IT

Funding

Università degli Studi di Trieste Microgrant LR 2/2011
6 · The paper itself

Abstract

backgroundRadiomorphometric indices measured on Dental Panoramic Radiography (DPR) can reflect Bone Mineral Density (BMD). The aim of our study is to evaluate changes in DPR radiographic markers in patients undergoing antiresorptive therapy with denosumab and correlate them to BMD and serum bone turnover markers (BTM).

methodsWe evaluated two radiomorphometric indices: Mandibular Cortical Width (MCW) and Panoramic Mandibular Index (PMI), in patients undergoing antiresorptive therapy with denosumab at T0 (before starting the therapy) and at T1 (after 12 months), comparing results with a control group of healthy patients who performed two DPRs at a one-year time distance. Correlation analysis was performed in the denosumab group, as well as ROC curves were obtained for both indices.

resultsThe study included 18 patients and 21 controls according to specific inclusion and exclusion criteria, matched by gender and age. Both MCW and PMI were significantly lower at T0 in the denosumab group, consistently with lower BMD. MCW showed significant correlation with femoral and lumbar DEXA and was significantly lower in patients with osteoporosis compared to osteopenia. Only PMI index increased significantly in the denosumab group from T0 to T1. After one year (T1), there weren't any differences between patients and controls for both indices. No significant correlations were found with BTMs. Sensitivity and specificity for MCW and PMI were also calculated.

conclusionsOur results show how CMW shows sufficient sensitivity and specificity to be used as a radiographic marker to screen and intercept patients with osteoporosis. PMI seems to be able to reflect changes in response to antiresorptive therapy with denosumab. Further studies are needed to confirm our hypothesis.

Indexed as

DenosumabOsteoporosisBiomarkersBone DensityCase-Control StudiesHumansMandibleRadiography, PanoramicRetrospective StudiesBiomarkersDenosumabAntiresorptive therapyBone metabolism markersBone Mineral DensityDenosumabDental panoramic radiography

Identifiers

PMID38229055
PMCPMC10792926
OpenAlexW4390909406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.